*CME/ACPE

Moderator:

Stacy E. Croteau, MD, MMS
Assistant Professor of Pediatrics, Harvard Medical School Director, Hemophilia/VWD Program, Boston Children's Hospital Medical Director, Boston Hemophilia Center 
Dana-Farber/Boston Children's Cancer Center & Blood Disorders Center
Boston, MA

Speakers:

Robert F. Sidonio, Jr, MD, MSc
Medical Director of Hemophilia Program
Director of Clinical Operations and Clinical Research
Aflac Cancer and Blood Disorders Center
Children's Healthcare of Atlanta/ Emory University
Atlanta, GA

Mark T. Reding, MD
Associate Professor of Medicine 
Division of Hematology, Oncology & Transplantation 
Director, Center for Bleeding and Clotting Disorders 
University of Minnesota Medical Center

 

By the end of this session, the participant should be better able to:

  • Describe the emerging therapies and novel non-factor approaches in development for treating patients with hemophilia A and B.
  • Discuss the mechanisms of action for FVIIIa mimetic bispecific antibodies and the assays needed to monitor their safety and efficacy
  • Recommend appropriate patients enroll in clinical trials for the evaluation of these therapies when and where available.